

# The Impact of hepatitis C virus (HCV) clearance on markers of immune aging and inflammation among women living with and without HIV over time.

### Julliet K. Zama<sup>1, 2, 3</sup>, Izabella Gadawski<sup>1</sup>, Hélène C. F. Côté<sup>1, 2, 3</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. <sup>2</sup>Centre for Blood Research, University of British Columbia, Vancouver, Canada. <sup>3</sup>Women's Health Research Institute, Vancouver, Canada.




Figure 1. HIV, HCV, and Premature Aging

### Objective


To characterize the effect of chronic HCV clearance on selected markers of immune aging and inflammation in women living with and without HIV.


### Hypotheses

Successful clearance of HCV will be associated with 1) slower loss of LTL, 2) increased mtDNA content, 3) increased CD4:CD8 ratio, and/or 4) a decrease in CD8+ T cell CD28-:CD28+ ratios, and 5) decreased markers of inflammation.

## Study Design

- This project is a longitudinal study **comparing several** markers of immune aging before and after HCV **clearance** among women aged ≥16 years living with HIV (study) and without HIV (controls).
- Participants are selected from 2 separate cohorts; the Children and Women AntiRetrovirals and Markers of Aging (CARMA) or the British Columbia CARMA-CHIWOS Collaboration (BCC3) with biospecimen collected pre and post-HCV clearance.





GROUPS		BASELINE		FOLLOW-UP	
		HIV status	HCV status	HIV status	HCV status
STUDY	HCV clearance	Positive	Ab+ RNA+	Positive	Ab+ RNA-
	HCV clearance	Negative	Ab+ RNA+	Negative	Ab+ RNA-
	Chronic HCV	Positive	Ab+ RNA+	Positive	Ab+ RNA+
CONTROL	Chronic HCV	Negative	Ab+ RNA+	Negative	Ab+ RNA+
	No HCV	Positive	Ab-	Positive	Ab-
	No HCV	Negative	Ab-	Negative	Ab-